Renal Cell Carcinoma Clinical Trials in Omaha, Nebraska

4 studies are recruiting for renal cell carcinoma in Omaha, Nebraska right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

  1. A Clinical Study of Belzutifan and Zanzalintinib in People With Recurrent Kidney Cancer Following Adjuvant Therapy (MK-6482-033)

    Researchers are looking for more ways to treat advanced renal cell carcinoma (RCC) that is recurrent. Researchers want to learn if recurrent advanced renal cell carcinoma (RCC) responds (gets smaller or goes away) after treatment with belzutifan (MK-6482) and zanzalintinib compared to cabozantinib.…

    Stage
    Phase 3
    Ages
    18 and older
    Site
    Oncology Hematology West P.C. dba Nebraska Cancer Specialists ( Site 0131), Omaha, Nebraska
    Locations
    127 in total
    Run by
    Merck Sharp & Dohme LLC

    See if you can join NCT07227402 on ClinicalTrials.gov

  2. Open-Label Phase 1/2 Study of NEO-811 in Subjects With Locally Advanced or Metastatic Non-Resectable Clear Cell Renal Cell Carcinoma

    The NEO-811-101 study is an open-label, first-in-human, Phase 1/2 dose escalation and expansion study testing NEO-811, an ARNT molecular glue degrader, in subjects with locally advanced or metastatic non-resectable clear cell renal cell carcinoma. The study will test NEO-811 initially as a monother…

    Stage
    Phase 1
    Ages
    18 and older
    Site
    NEO-811 Omaha Site, Omaha, Nebraska
    Locations
    12 in total
    Run by
    Neomorph, Inc

    See if you can join NCT07300241 on ClinicalTrials.gov

  3. Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)

    This is a Phase 1/2, open-label, non-randomized, 4-part trial to determine the safety profile and identify the maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D) of INBRX 106 administered as a single agent or in combination with the anti-PD-1 checkpoint inhibitor (CPI) pembrolizuma…

    Stage
    Phase 1
    Ages
    18 and older
    Site
    Nebraska Cancer Specialists, Omaha, Nebraska
    Locations
    42 in total
    Run by
    Inhibrx Biosciences, Inc

    See if you can join NCT04198766 on ClinicalTrials.gov

  4. A Study of Pazopanib With or Without Abexinostat in Patients With Locally Advanced or Metastatic Renal Cell Carcinoma (RENAVIV)

    This is a randomized, Phase 3, double-blind, placebo-controlled study of pazopanib plus abexinostat versus pazopanib plus placebo in patients with locally advanced unresectable or metastatic renal cell carcinoma (RCC).

    Stage
    Phase 3
    Ages
    18 and older
    Site
    GU Research Network/Urology Cancer Center, Omaha, Nebraska
    Locations
    38 in total
    Run by
    Xynomic Pharmaceuticals, Inc.

    See if you can join NCT03592472 on ClinicalTrials.gov

How to read this page. Every study here comes from ClinicalTrials.gov, the public registry that research teams are required to file with. We have summarised each one in plain language and shown where it is running. We have not changed what any study says it is doing.

What TrialBoost is. We help people find research that might suit them, and, if they ask us to, we pass their details to the research team running it. We are not a doctor, a research site, or a study sponsor, and we do not decide who takes part in anything. Joining costs nothing and you can change your mind at any point.

Paid placement. Some studies pay us when someone asks to be connected to them. Those are labelled Sponsored wherever they appear, and they only appear when they match what you were actually looking for.